Concepedia

Michael Kohen

MK

Statistics

Publications

3

Citations

925

H-Index

3

Active since

2008

Affiliations

Ono Pharmaceutical (United States)(Current)

Michael Kohen is an author at Ono Pharmaceutical (United States) specializing in rheumatology, medicine, and inflammatory arthritis.

Publications per year

2008–2020

3

Publications

3

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 652 citations · Full text

, , +4

Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study

Mark C. Genovese, Jeffrey Kaine, Mitchell B. Lowenstein et al. · Arthritis & Rheumatism · 2008 · 205 citations

, , +16

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

Dona Fleishaker, Juan A. García Meijide, Michael Kohen et al. · Arthritis Research & Therapy · 2012 · 68 citations · Full text

, , +14

1–3 of 3